Telomir Pharmaceuticals, Inc. (TELO) - 10-Q Summary
Business Context and Reporting Period
Telomir Pharmaceuticals, Inc. is a pre-clinical stage biotechnology company developing Telomir-1, an oral small molecule designed to target epigenetic mechanisms underlying cancer, aging, and degenerative diseases. This report covers the quarterly period ended September 30, 2025. The company is classified as a smaller reporting company and an emerging growth company.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Loss | $(1,102,294) | $(5,990,733) | $(8,352,012) | $(13,634,343) |
| Loss Per Share (Basic/Diluted) | $(0.03) | $(0.20) | $(0.27) | $(0.46) |
| Research & Development Expenses | $759,525 | $627,434 | $1,139,360 | $1,966,258 |
| General & Administrative Expenses | $386,951 | $5,378,744 | $7,264,808 | $6,999,981 |
| Cash and Cash Equivalents (End of Period) | $7,329,298 (as of Sept 30, 2025) Working Capital: $6,979,310 Total Liabilities: $422,807 |
|||
Material Changes vs. Prior Period
- Net Loss Reduction: Net loss decreased significantly in Q3 2025 compared to Q3 2024, primarily due to a reduction in General and Administrative (G&A) expenses. Q3 2024 G&A included substantial stock-based compensation charges that were not repeated in the current quarter.
- Operating Expenses: YTD 2025 R&D expenses decreased by approximately $827,000 compared to YTD 2024, attributed to the absence of specific pharmaceutical manufacturing activities incurred in the prior year.
- Capital Structure: The company raised significant capital in 2025, including $3.0 million from a related party (The Bayshore Trust) and approximately $5.55 million through its At-The-Market (ATM) facility, increasing cash reserves from $1.27 million at year-end 2024 to $7.33 million.
- Interest Expense: Interest expense was negligible in 2025 compared to $4.3 million in YTD 2024, which included the amortization of deferred financing costs on a related party line of credit that is no longer active.
Outlook, Risks, and Unusual Items
- Going Concern: Management has raised substantial doubt about the company's ability to continue as a going concern for the next 12 months. Current cash is projected to fund operations only through the third quarter of 2026. Additional equity or debt financing is required to continue operations and clinical trials.
- Strategic Acquisition: On October 17, 2025, the company executed a binding Letter of Intent (LOI) to acquire TELI Pharmaceuticals, Inc. This transaction aims to secure worldwide rights to Telomir-1, consolidating U.S. and ex-U.S. intellectual property. The deal includes potential contributions of up to $5 million from TELI shareholders contingent on milestones (closing, IND acceptance, Phase 1/2 initiation).
- Recent Financing: Subsequent to the quarter end, on October 9, 2025, the company sold 550,000 shares via its ATM facility for net proceeds of approximately $1.0 million.
- Preclinical Progress: The company reported multiple preclinical data points in Q3 and October 2025 regarding Telomir-1's efficacy in prostate, pancreatic, and breast cancer models, as well as its ability to reverse epigenetic silencing and restore mitochondrial function in aging models.
Investor Verification Checklist
- Capital Runway: Verify the sufficiency of the $7.3 million cash balance against the projected burn rate to confirm the timeline for the next funding round.
- Acquisition Status: Monitor the progress of the TELI Pharmaceuticals acquisition, specifically the negotiation of definitive agreements and shareholder approvals required to close the deal.
- Dilution Risk: Assess the impact of ongoing ATM offerings and potential future equity raises required to fund clinical trials.
- Related Party Transactions: Review the terms of the $3 million investment from The Bayshore Trust and the $5 million credit facility with the Starwood Trust for potential conflicts or repayment obligations.
- Regulatory Path: Confirm the timeline for the Investigational New Drug (IND) application, as this is a key milestone for both the acquisition funding and clinical progression.